Potential Therapy, Niraparib, Available to Select Patients in Europe via Managed Access Program

Potential Therapy, Niraparib, Available to Select Patients in Europe via Managed Access Program
Recurrent ovarian cancer patients in Europe with few or no treatment options may soon have access to an investigational therapy, niraparib, under a managed access program launched by Tesaro, the drug’s developer, and the British-based Clinigen Group. The European Medicines Agency is considering recommending niraparib as a maintenance treatment for people with recurrent ovarian cancer and a complete or partial response to platinum-based chemotherapy, under a marketing authorization

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *